Samba Scientific’s Post

I spoke with BioCentury Inc.'s Paul Bonanos to discuss biopharmaceutical dynamics, following the release of Lazard's 2024 Global Biopharmaceutical Leaders Study. Our Study revealed an expected uptick in bolt-on M&A and collaborations driven by the need to drive growth, replenish pipelines, and strengthen franchises. Biopharma leaders indicated that artificial intelligence and machine learning are already affecting innovation, with 43% of respondents highlighting their impact on chemistry discovery. Over the next five years, we expect AI and machine learning to increasingly influence clinical development. Despite economic and geopolitical uncertainties, there is a sense of optimism among investors and executives in the biopharmaceutical sector about innovation, M&A, and the ability to finance. Click here to read the full interview: https://lnkd.in/e9-RknMj #Healthcare #Biotech #HealthcareInnovation #Biotechnology

🌾 𝗪𝗵𝗲𝗮𝘁'𝘀 𝗪𝗲𝗲𝗸𝗹𝘆!! 🌾 #wheatsweekly - Not the best week for lay offs in the CDMO industry, so let's highlight some other more positive news (excluding the second point)! 𝗕𝗿𝗲𝗮𝗸𝗶𝗻𝗴 𝗡𝗲𝘄𝘀 ✅ Scorpius BioManufacturing, Inc. has announced the successful validation of its microbial facilities, making it cGMP approved! 🔐 WuXi Biologics is added to the Biosecure Act list of companies for concern due to the current geopolitical issues 𝗠&𝗔 𝗼𝗳 𝘁𝗵𝗲 𝘄𝗲𝗲𝗸 🤝 ExcellGene SA and Cytovance Biologics enter a strategic partnership to advance their biologics services. 🇨🇳 Anhui Ribobay Pharmaceutical Co.,Ltd. integrates Cytiva's FlexFactory platform to rapidly expand its oligo CRDMO business 𝗘𝘅𝗽𝗮𝗻𝘀𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝘄𝗲𝗲𝗸 🏭 Renaissance Lakewood, LLC has opened their new 81,000 sq. ft. HQ in New Jersey 🧬 Aldevron have expanded its capabilities in mRNA LNP encapsulation by entering a strategic partnership with Acuitas Therapeutics 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 𝗼𝗳 𝘁𝗵𝗲 𝘄𝗲𝗲𝗸 💰 Aardvark Therapeutics has announced an $85 million oversubscribed Series C financing led by Decheng Capital 𝗡𝗲𝘄 𝗟𝗲𝗮𝗱𝗲𝗿𝘀𝗵𝗶𝗽 🌟 mAbxience names Jurgen Van Broeck as new CEO 👩🔬 Teva Pharmaceuticals has appointed Matt Shields as Executive Vice President of Teva Global Operations Did I miss anything, let me know in the comments! 👇 hashtag #CDMO hashtag #pharma hashtag #biotech

🧪 Labs play an integral role in the “molecule-to-medicine” value chain, directly impacting the #PharmaIndustry's most critical goals: accelerating drug discovery, reducing costs, and improving success rates. 🥼 And pharma and #biopharma companies are taking notice: Nearly 75% of respondents in our survey say their organizations have begun lab modernization. Have you begun developing your very own #LabOfTheFuture? Download our report for actionable recommendations based on our learnings from the leaders 📥 https://bit.ly/3OwCgCV #DigitalLab #PharmaInnovation #LifeSciences #CapgeminiLifeSciencesandHealthcare

Important topic. Labs are not (just) those places where new therapies are invented and tested. Labs are also the production sites of the new therapies, like Cell&Gene, hence Lab modernization becomes a critical path.

Congratulations to our portfolio company, Insilico Medicine, for winning the 2024 Fierce 50 award from Fierce Life Sciences and Fierce Healthcare. According to Ayla Ellison, Editor-in-Chief of Fierce Life Sciences and Healthcare, the annual Fierce 50 special report highlights individuals and companies that are driving progress in the pharmaceutical, healthcare, and biotechnology industries. These 50 outstanding organizations and individuals demonstrate excellence in their fields, and their commitment to innovation, equity, and improving lives is truly commendable. Powered by Pharma.AI, Insilico Medicine has nominated 20 preclinical candidates in its comprehensive portfolio of over 30 assets, with 9 molecules receiving IND approval. #Fierce50 #PharmaAI #BiotechInnovation #HealthcareAwards #PreclinicalResearch #INDApproval #Pharmaceuticals #Innovation #Biotechnology #LifeSciences #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/gpYEaupN

🇩🇪 Germany: A Powerhouse in the Global Biopharma Landscape Germany continues to solidify its position as a global leader in biopharmaceuticals, driven by substantial R&D investments, supportive regulations, and a thriving ecosystem of innovative industry players. As the country focuses on advancing infrastructure and fostering innovation, its growth trajectory remains strong, positioning Germany as a key player in biopharmaceutical production and innovation. ✨Are you looking to connect with top German biotech and biopharma companies? Don’t miss Biologics Manufacturing Germany 2024! This event will dive deep into the latest advancements in biomanufacturing, addressing how increasing operational complexity and uncertainty are influencing long-term decision-making. Key topics include risk mitigation, navigating regulatory changes, and selecting the right CMO partners—especially in the context of emerging trends like automation, AI, and sustainability. For anyone involved in biologics manufacturing, this is an essential opportunity to gain insights on tackling challenges and making informed decisions in a rapidly evolving landscape. Let's shape the future of biopharma together! 💡 Find more information: https://lnkd.in/e26KNYVr #Biopharma #Biotech #Germany #Innovation #Biomanufacturing #Automation #AI #Sustainability

Exciting News! BioLink has successfully completed its Series A+ strategic financing round! Led by several top-tier investors, along with continued support from existing shareholders, this round has raised the target funding. This tremendous support underscores the confidence in BioLink's vision and potential for growth. As a professional lifescience company, BioLink is committed to continuously providing customers with high-quality innovative products and solutions. "Link to enable biotechnologies", our vision is to create an efficient, safe, and competitive biopharmaceutical supply chain ecosystem for our customers. This financing round will fuel our efforts in research and development, technological advancement, and international market expansion. We remain committed to our core values of innovation, quality, and customer satisfaction as we continue to tackle challenges and refine our product portfolio. A huge thank you to our investors for their unwavering support, and to our incredible team for their dedication and hard work. Together, we're shaping the future of biotechnology and driving progress in the biopharmaceutical industry. Stay tuned for more updates on our journey! #BioLink #BiotechInnovation #Bioprocessing #InvestmentSuccess https://lnkd.in/gbjRsKDs

Here are more insights from the Precision in Drug Discovery & Preclinical Summit!🌟 Exciting insights and valuable networking moments captured during the event. It’s inspiring to see industry leaders come together to drive innovation in drug discovery and development! #PDDPSummit #DrugDiscovery #HealthcareInnovation #NetworkingEvent #PrecisionMedicine #LifeSciences #Biotech #Pharma #PharmaceuticalResearch #SanDiegoEvents #IndustryLeadership

2024 has become a year of disruption in biopharma manufacturing. From major acquisitions, to the Biosecure Act and incoming regulatory changes, to the new wave of biologics treatments driving growth. At a time when 90% of biotechs rely on contract manufacturing, one thing is clear - the future of biopharma is driven by and enabled by CDMOs. Join us online on June 13, 2024 for CDMO Live—an exclusive event spotlighting the pivotal role of outsourcing in pharma and biotech. Gain insights, network, and stay ahead of the curve in this dynamic industry. Claim your complimentary ticket: https://lnkd.in/dfyP9iD8 The four hour online event will cover: ⚡ Lightning Talks: Two tracks of rapid-fire expert insights and analysis of the contract development & manufacturing landscape: 💡 Interactive Roundtables: Share best practices in critical topics - from RFPs to Talent; Sustainability to AI Manufacturing. 🤝 PartnerMatch: Approved buyers can take part in 121 curated meetings with innovative CDMO partners who can fast-track your products: #CDMOLive